SABCS: Shorter Chemotherapy Regimen Plus Taxol Reduces Breast Cancer Recurrence
12th Dec 2005, 20:36 GMT
SAN ANTONIO - A shorter standard adjuvant chemotherapy regimen, augmented by weekly doses of Taxol (paclitaxel), led to a 37% reduction in the relative risk of recurrence of node-positive breast cancer, a Spanish study concluded.
SABCS: Shorter Chemotherapy Regimen Plus Taxol Reduces Breast Cancer Recurrence related news:
- SABCS: Taxotere-Cytoxan Combo Shows Survival Advantage in Breast Cancer Adjuvant Therapy — MedPage Today.com Latest Headlines
- Novartis drug helps prevent breast cancer recurrence — Pharmaceutical Business Review Online
- SABCS: Dose-Dense Chemotherapy Called Safe and Effective — MedPage Today Hematology/Oncology
- Low-dose Chemotherapy Plus Antiangiogenesis Drug Has Activity In Advanced Breast Cancer — ScienceDaily Headlines: Health & Medicine
- Dose-Dense Adjuvant Chemo Regimen Safe, More Effective for Selected Breast Cancer Patients — Medscape Medical News Headlines
- Breast cancer treatment changing — The Cancer Blog
- Survival Benefit For Arimidex™ In Early Breast Cancer — Medical News Today RSS/XML Feed
- Fatigue fairly uncommon after breast cancer chemo (Reuters) —
- Radiotherapy aids breast cancer survival — MSNBC.com: Health
- Fatigue fairly uncommon after breast cancer chemo — RedOrbit News - Health